KRRO

Korro Bio, Inc.
CAPPED RATING

Korro Bio, Inc. (KRRO) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C-
Factor Score 2.0 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.4
EV / EBITDA -1.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 7.8%
Price Return 12M -56.4%
Catalyst Signal 0.00
Market Cap $196.4M
TTM Revenue $1.3M
Price / Sales 152.0
ROE -113.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C- (2.0) D (1.2) D (1.4) C (2.4) C+ (2.6) C- (2.0)
2026-11-06 C (2.5) B- (3.0) D+ (1.6) C+ (2.5) C+ (2.7) C (2.4)
2026-10-30 C (2.5) B- (2.9) D (1.5) C (2.4) C+ (2.7) C (2.4)
2026-10-23 C+ (2.6) B- (2.9) D (1.5) C (2.2) C+ (2.6) C (2.4)
2026-10-16 C+ (2.7) B- (2.9) D (1.5) C- (2.1) C+ (2.6) C (2.4)
Page 1 of 4